ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
ByKaryn A. Goodman, MD,Sarah A. Milgrom, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Theodore S. Hong, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Miguel Rodriguez-Bigas, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.
